Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

被引:68
|
作者
Melegaro, Alessia [1 ,2 ]
Choi, Yoon Hong [1 ]
George, Robert [1 ]
Edmunds, W. John [1 ,3 ]
Miller, Elizabeth [1 ]
Gay, Nigel J. [1 ,2 ]
机构
[1] Hlth Protect Agcy, Ctr Infect, London NW9 5EQ, England
[2] Bocconi Univ, DONDENA Ctr Res Social Dynam, Milan, Italy
[3] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England
关键词
STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; TRANSMISSION PARAMETERS; EPIDEMIOLOGIC EVIDENCE; COST-EFFECTIVENESS; HAEMOPHILUS-INFLUENZAE; ACQUIRED-IMMUNITY; SOCIAL CONTACTS; MIXING PATTERNS; DOUBLE-BLIND;
D O I
10.1186/1471-2334-10-90
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The Gambia). However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be countered by serotype replacement. Method: A dynamic, age-structured, compartmental model of Streptococcus pneumoniae transmission was developed to predict the potential impact of PCV7 on the incidence of invasive disease accounting for both herd immunity and serotype replacement effects. The model was parameterised using epidemiological data from England and Wales and pre and post-vaccination surveillance data from the US. Results: Model projections showed that serotype replacement plays a crucial role in determining the overall effect of a PCV7 vaccination programme and could reduce, negate or outweigh its beneficial impact. However, using the estimate of the competition parameter derived from the US post-vaccination experience, an infant vaccination programme would prevent 39,000 IPD cases in the 20 years after PCV7 introduction in the UK. Adding a catch-up campaign for under 2 or under 5 year olds would provide a further reduction of 1,200 or 3,300 IPD cases respectively, mostly in the first few years of the programme. Conclusions: This analysis suggests that a PCV vaccination programme would eradicate vaccine serotypes from circulation. However, the increase in carriage of non-vaccine serotypes, and the consequent increase in invasive disease, could reduce, negate or outweigh the benefit. These results are sensitive to changes in the protective effect of the vaccine, and, most importantly, to the level of competition between vaccine and non-vaccine types. The techniques developed here can be used to assess the introduction of vaccination programmes in developing countries and provide the basis for cost-effectiveness analyses.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review
    Tin Tin Htar Myint
    Harish Madhava
    Paul Balmer
    Dina Christopoulou
    Sepideh Attal
    Damianos Menegas
    Ralf Sprenger
    Eric Bonnet
    [J]. Advances in Therapy, 2013, 30 : 127 - 151
  • [32] Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia
    Gidding, Heather E.
    Sheridan, Sarah
    Fathima, Parveen
    Moore, Hannah C.
    Liu, Bette
    McIntyre, Peter B.
    Palmu, Arto A.
    Snelling, T. S.
    de Klerk, N.
    Andrews, R. M.
    Blyth, C. C.
    Richmond, P.
    Jorm, L.
    Sheppeard, V
    Effler, P.
    Menzies, R.
    Hull, B.
    Joseph, T.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (08) : 860 - 865
  • [33] The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review
    Myint, Tin Tin Htar
    Madhava, Harish
    Balmer, Paul
    Christopoulou, Dina
    Attal, Sepideh
    Menegas, Damianos
    Sprenger, Ralf
    Bonnet, Eric
    [J]. ADVANCES IN THERAPY, 2013, 30 (02) : 127 - 151
  • [34] The conjugate vaccine and invasive pneumococcal disease - Reply
    Whitney, CG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 715 - 716
  • [35] Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use
    Yildirim, Inci
    Lapidot, Rotem
    Shaik-Dasthagirisaheb, Yazdani Basha
    Hinderstein, Sarah
    Lee, Hanna
    Klevens, Monina
    Grant, Lindsay
    Mohs, Adriano Gerardo Arguedas
    Cane, Alejandro
    Madoff, Larry
    Johnson, Hillary
    Ivanof, Caryn
    Burns, Meagan
    Pelton, Stephen
    [J]. PEDIATRICS, 2024, 153 (01)
  • [36] Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
    van Deursen, Anna M. M.
    van Mens, Suzan P.
    Sanders, Elisabeth A. M.
    Vlaminckx, Bart J. M.
    de Melker, Hester E.
    Schouls, Leo M.
    de Greeff, Sabine C.
    van der Ende, Arie
    [J]. EMERGING INFECTIOUS DISEASES, 2012, 18 (11) : 1729 - 1737
  • [37] DECLINE IN INVASIVE PNEUMOCOCCAL DISEASE IN IRELAND SINCE INTRODUCING THE PNEUMOCOCCAL CONJUGATE VACCINE
    Fitzgerald, M.
    Vickers, I.
    Lorcain, P. O'
    Murchan, S.
    Cotter, S.
    O'Flanagan, D.
    Cafferkey, M.
    Humphreys, H.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : 229 - 229
  • [38] Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine
    Stokley, Shannon
    Shaw, Kate M.
    Barker, Lawrence
    Santoli, Jeanne M.
    Shefer, Abigail
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2006, 96 (07) : 1308 - 1313
  • [39] Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era
    Martin, Olufunke O.
    Moquist, Kristin L.
    Hennessy, Jane M.
    Nelson, Stephen C.
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 (01)
  • [40] Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations (vol 65, pg 1780, 2017)
    Naucler, P.
    Galanis, I
    Morfeldt, E.
    Darenberg, J.
    Ortqvist, A.
    Henriques-Normark, B.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 (01) : 175 - 175